MediWound Ltd (NASDAQ: MDWD, FNEWS: FNEWS), a biopharmaceutical company focused on enzymatic treatments for burns and chronic wounds, has disclosed that three senior leaders collectively paid $418,237 in cash to exercise warrants and acquire 31,038 ordinary shares ahead of a 28 November expiry deadline. The transactions, filed on 12 November, saw Chairman Nachum "Homi" Shamir, Chief Executive Ofer Gonen, and director David Morton Fox each retain every share acquired without selling. The commitment arrives as NexoBrid, the company's FDA-approved burn treatment, reports accelerating hospital adoption, and pivotal Phase 3 data for investigational EscharEx approaches a first interim checkpoint.
Key Points
- MediWound Ltd (NASDAQ: MDWD, FNEWS: FNEWS) — biopharmaceutical company developing enzymatic wound treatments
- Chairman Shamir, CEO Gonen, and director Fox paid a combined $418,237 to exercise warrants at $13.475 per share, acquiring 31,038 ordinary shares
- Warrant expiry of 28 November provided timing context; no shares were sold; executives accepted 60-day lockup restrictions following a recent offering
- Investors may be watching the EscharEx Phase 3 VALUE trial interim checkpoint, expected by end of Q1 2027
Shamir, Gonen and Fox Exercise Warrants at $13.475 Ahead of 28 November Expiry
Chairman Nachum "Homi" Shamir acquired the largest individual stake, purchasing 16,336 shares for approximately $220,128. Chief Executive Ofer Gonen acquired 8,168 shares for roughly $110,064, while director David Morton Fox acquired 6,534 shares for approximately $88,046. All three paid in cash at the fixed exercise price of $13.475 per share. The filings confirm that none of the shares acquired were subsequently sold, and the executives also accepted 60-day lockup restrictions on selling in connection with a recent November offering, reinforcing their alignment with the company's near-term development milestones.
NexoBrid Records Repeat Orders at More Than 70 Burn Centres Across North America
NexoBrid is an FDA-approved enzymatic treatment that removes dead tissue from deep partial-thickness and full-thickness thermal burns, offering clinicians a drug-based alternative to surgical debridement. Commercial partner Vericel (NASDAQ: VCEL) reported record quarterly NexoBrid revenue of $2.3 million in the third quarter of 2026, up 54% year-on-year, alongside $3 million in federal procurement revenue. MediWound's November update stated that more than 80 burn centres had ordered the product, with approximately 70 placing repeat orders. The announcement notes that more new ordering centres were added through the first nine months of 2026 than during the whole of 2025.
EscharEx Phase 3 VALUE Trial Targets 216 Patients With Interim Checkpoint Expected by March 2027
Investigational EscharEx applies MediWound's enzymatic debridement approach to chronic wounds, with venous leg ulcers as the initial indication. Phase 2 exploratory data cited in the announcement showed that 50% of EscharEx patients achieved complete dead-tissue removal and healthy granulation tissue coverage within two weeks, compared with none in a small collagenase ointment comparator subgroup. The Phase 3 VALUE trial targets 216 patients across approximately 40 sites. MediWound expects enrollment completion and an interim sample-size reassessment by the end of Q1 2027. An independent consulting firm's assessment, as reported by MediWound, estimates $1.05 billion in potential annual US peak sales across venous leg ulcers, diabetic foot ulcers, and pressure ulcers, contingent on further development and approvals.



Please wait processing your request...